# A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors

> **NCT07715747** · PHASE1 · NOT_YET_RECRUITING · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Solid Tumor
- Metastatic Ovary Cancer
- Metastatic Gastric Cancer
- Metastatic Endometrial Carcinoma

## Interventions

- **DRUG:** TJ037130

## Key facts

- **NCT ID:** NCT07715747
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715747, "A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*